Abstract

The application represents an interdisciplinary approach to improving prevention, diagnosis, and treatment of prostate cancer. UCSF basic scientists and clinical investigators with diverse talents in cell and molecular biology, immunology, genetics, as well as informatics, biostatistics, and conducting phase I studies in prostate cancer are working together to address important problems in this disease. Four projects specifically are designed to improve treatment of advanced prostate cancer using either 1) anti-CTLA4 antibodies 2) mutant adenoviruses and radiation therapy, 3) recombinant human antibodies against prostate cancer antigens, and 4) mutant telomerases. One of the projects will identify new prostate cancer antigens using antibody gene diversity libraries and phage display. In addition, one project is focused on identifying the genetic aberrations in prostate cancer responsible for development and progression of the disease. A related project is focused on identifying modifier genes which determine whether patients develop prostate cancer metastases. Several Cores will provide critical support to the Projects including Cores focused on: Informatics, Clinical Research, Animal Technology; Tissue acquisition and storage, and Administration. In addition, members of a recently formed Prostate Cancer Advocacy Core will work with SPORE investigators to design, and implement optimal approaches to clinical trials.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA089520-05S2
Application #
7124478
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Hruszkewycz, Andrew M
Project Start
2000-09-25
Project End
2009-06-30
Budget Start
2004-09-13
Budget End
2009-06-30
Support Year
5
Fiscal Year
2005
Total Cost
$60,000
Indirect Cost

  Institution

Name
University of California San Francisco
Department
Urology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143

  Publications

Belair, Cassandra D; Paikari, Alireza; Moltzahn, Felix et al. (2015) DGCR8 is essential for tumor progression following PTEN loss in the prostate. EMBO Rep 16:1219-32
Glass, Allison S; Hilton, Joan F; Cowan, Janet E et al. (2014) Serial prostate biopsy and risk of lower urinary tract symptoms: results from a large, single-institution active surveillance cohort. Urology 83:33-8
Huang, Vera; Place, Robert F; Portnoy, Victoria et al. (2012) Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res 40:1695-707
Place, Robert F; Wang, Ji; Noonan, Emily J et al. (2012) Formulation of Small Activating RNA Into Lipidoid Nanoparticles Inhibits Xenograft Prostate Tumor Growth by Inducing p21 Expression. Mol Ther Nucleic Acids 1:e15
Hilton, Joan F; Blaschko, Sarah D; Whitson, Jared M et al. (2012) The impact of serial prostate biopsies on sexual function in men on active surveillance for prostate cancer. J Urol 188:1252-8
Punnen, Sanoj; Cooperberg, Matthew R; Sadetsky, Natalia et al. (2012) Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores? BJU Int 109:1520-4
Ross, Hillary M; Kryvenko, Oleksandr N; Cowan, Janet E et al. (2012) Do adenocarcinomas of the prostate with Gleason score (GS) ýýý6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 36:1346-52
Busch, Sarah; Hatridge, Michael; Mößle, Michael et al. (2012) Measurements of T(1) -relaxation in ex vivo prostate tissue at 132 ?T. Magn Reson Med 67:1138-45
Cooperberg, Matthew R; Cowan, Janet E; Hilton, Joan F et al. (2011) Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 29:228-34
Abe, Miyako; Xie, Wanling; Regan, Meredith M et al. (2011) Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int 107:126-34

Showing the most recent 10 out of 127 publications